Efficient generation of transgenic pigs using equine infectious anaemia virus (EIAV) derived vector  by Whitelaw, C.Bruce A et al.
FEBS 28632 FEBS Letters 571 (2004) 233–236Eﬃcient generation of transgenic pigs using equine infectious
anaemia virus (EIAV) derived vectorC. Bruce A. Whitelawa,*, Pippa A. Radcliﬀeb, William A. Ritchiea, Ailsa Carlislea,
Fiona M. Ellardb, Romi N. Penac, Jo Rowea, A. John Clarka, Tim J. Kinga,
Kyriacos A. Mitrophanousb
aDepartment of Gene Function and Development, Roslin Institute, Roslin, Midlothian EH25 9PS, UK
bOxford BioMedica, The Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA, UK
cArea de Produccio Animal, UdL-IRTA, 25198 Lleida, Spain
Received 21 June 2004; accepted 23 June 2004
Available online 8 July 2004
Edited by Jesus AvilaAbstract Traditional methods of transgene delivery in livestock
are ineﬃcient. Recently, human immunodeﬁciency virus (HIV-1)
based lentiviral vectors have been shown to oﬀer an eﬃcient
transgene delivery system. We now extend this method by
demonstrating eﬃcient generation of transgenic pigs using an
equine infectious anaemia virus derived vector. We used this
vector to deliver a green ﬂuorescent protein expressing trans-
gene; 31% of injected/transferred eggs resulted in a transgenic
founder animal and 95% of founder animals displayed green
ﬂuorescence. This compares favourably with results using HIV-1
based vectors, and is substantially more eﬃcient than the
standard pronuclear microinjection method, indicating that
lentiviral transgene delivery may be a general tool with which
to eﬃciently generate transgenic mammals.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The generation of transgenic animals holds considerable
promise to advance understanding in biomedical and agricul-
tural systems. Nevertheless, applications in livestock have been
restricted by the considerable eﬀort and cost required to gen-
erate individual animals. The recent development of lentiviral
vectors for transgene delivery [1–4] may overcome some of
these limitations.
The ﬁrst transgenic livestock were generated nearly two
decades ago using the pronuclear microinjection technique [5],
which involves the direct injection of the transgene DNA into* Corresponding author. Fax: +44-131-440-0434.
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Abbreviations: CMV, cytomegalovirus; GFP, green ﬂuorescent pro-
tein; EIAV, equine infectious anaemia virus; HIV, human immuno-
deﬁciency virus
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doi:10.1016/j.febslet.2004.06.076one of the two pronuclei in the zygote. Although ineﬃcient,
with 1% of injected eggs resulting in a transgenic founder an-
imal, the reliability of pronuclear injection has ensured that it
remains the most used method [6]. Alternative methods have
been developed. The use of transgenic sperm to generate
transgenic livestock is attractive due to its simplicity but suﬀers
from apparent variability [7], while nuclear transfer using
transgenic cells [8] has the advantage that all founder animals
should be transgenic but is currently severely restricted due to
very low foetal survival and high neonatal mortality [9].
Recently, transgenic mammals have been generated using a
lentiviral vector [1–4]. In contrast to using an oncoretroviral
vector [10], lentiviral delivery appears to oﬀer a spectacularly
eﬃcient method for the generation of transgenic mammals.
The lentiviral vector can be introduced by injection into the
perivitelline space of the zygote [2,3] or by co-culture with a
zona-free zygote [1]. In mice, 10–30% of lentivirus-infected
eggs can give rise to transgenic founder animals with 60–90%
of these founders expressing the transgene [1,2]. Similar fre-
quencies have been obtained in pigs [3] and cattle; the latter
only successful by infecting oocytes that are subsequently
fertilised in vitro [4]. This should be compared to the standard
pronuclear injection method where 5% of mouse zygotes and
1% of livestock zygotes result in a transgenic founder animal
[6].
All reports on lentiviral transgenic mammals to-date have
used an human immunodeﬁciency virus (HIV-1) based vector
[1–4,11–13]. We now show that a vector based on another
lentivirus, the equine infectious anaemia virus (EIAV), can
also be used to eﬃciently generate transgenic mammals. This
suggests that lentiviral transgene delivery may be a general tool
with which to eﬃciently generate transgenic mammals.2. Materials and methods
2.1. EIAV vector production
The method for generating EIAV based vectors has been previously
described [14]. Brieﬂy, HEK293T cells were seeded in DMEM sup-
plemented with 10% (v/v) foetal calf serum (FCS), 2 mM L-glutamine
and 1MEM non-essential amino acids at a density of 4.4 104 cm2.
The next day, cells were transfected with the pESYNGP (an EIAV
codon optimised gag/pol expression construct: Wilkes et al., manu-
script in preparation), pRV67 (a VSV-G envelope expression plasmid)ation of European Biochemical Societies.
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green ﬂuorescent protein (GFP) under the control of the human cy-
tomegalovirus immediate-early enhancer/promoter (CMV) (Wilkes et
al., manuscript in preparation), using Fugene-6 (Roche). Sixteen hours
after transfection, the cells were treated with 10 mM sodium butyrate
for 6 h and then the culture medium was replaced with butyrate-deﬁ-
cient medium. At 40 h post transfection, the culture medium was
collected, centrifuged at 1000 g for 5 min and ﬁltered through a 0.45
lM ﬁlter unit. The vector was concentrated by low speed centrifuga-
tion (6000 g, for 16 h at 4 C) followed by ultracentrifugation
(50 000 g, for 90 min at 4 C). The vector was resuspended in TSSM
buﬀer consisting of sodium chloride (100 mM), Tris, pH 7.3 (20 mM),
sucrose (10 mgml) and mannitol (10 mgml), aliquoted and stored at
)80 C. Vector titres on D17 cells were 1.6 109 TU/ml.Fig. 1. EIAV vector. Schematic representation of the EIAV (pO-
NY8.7NCG) vector used in this study. The vector contains a self-in-
activating long terminal repeat (SIN LTR), Woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE) and central polypurine
tract (cPPT). Expression of EGFP transgene is under the control of the
hCMV promoter. Expression of the Neo gene is minimal in transduced
cells due to the SIN LTR.2.2. Zygote collection and infection
Embryos were obtained from Large-White gilts that were approxi-
mately 9 months of age and weighed at least 120 kg at the time of use.
Super-ovulation was achieved by feeding 20 mg altrenogest (Regu-
mate, Hoechst Roussel Vet. Ltd.) once daily for 4 days, between day 11
and 15 following an observed oestrus, and twice on the 5th day. On the
6th day, 1500 IU of equine chorionic gonadotropin (pregnant mare’s
serum gonadotropin, Intervet UK Ltd.) was injected at 20:00 h. Eighty
three hours later, 750 IU human chorionic gonadotropin (Chorulon,
Intervet UK Ltd.) was injected. Donors gilts were mated twice every 6
h apart from a Large White boar after exhibiting heat generation
following super-ovulation. Embryos were surgically recovered from
mated donors by mid-line laparotomy under general anaesthesia on
day 1 following oestrus (heat¼oestrus Day 0).
Zygotes were recovered by ﬂushing the oviducts of ﬁve gilts with
warm phosphate buﬀered saline with the addition of 1% foetal calf
serum. They were removed from the PBS and stored in HEPES North
Carolina State University 23 medium (HNCSU 23 medium) at 38 C
with the addition of 10% FCS. 70–80 pl of virus suspension was in-
jected into the peri-vitelline space of the zygotes, using a ‘‘WPI PV820
Pico Pump’’. A few zygotes were kept from each donor animal and the
remainder of the zygotes was mixed and transferred back into syn-
chronous recipient animals.
Recipient females were treated identically to donor gilts but re-
mained un-mated. After treatment, fertilised embryos were transferred
to recipient gilts following a mid-line laparotomy under general an-
aesthesia. During surgery, the reproductive tract was exposed and
embryos were transferred into the oviduct of recipients using a
Drummond positive displacement micropipette.
Zygotes to be maintained in vitro to assess GFP activity were
transferred to micro drops of HNCSU 23 medium and cultured at 38
C in a 5% CO2 atmosphere.2.3. Southern blot
Lentiviral transgene integration number was determined by South-
ern blot analysis of DNA from an ear biopsy. 10 lg of DNA was
digested with ScaI, separated on a 0.5% agarose gel, blotted to a nylon
membrane and probed with a 570 bp-long PCR ampliﬁed fragment
from the pEGFP-N1 plasmid (Clontech) using primers GFP-forward
50-CGAGGGCGATGCCACCTAC-30 and GFP-reverse 50-CTCCA-
GCAGGACCATGTGATC-30. For complete restriction and loading
control, we stripped the blots in boiling 0.5% SDS, 0.1 SSC and
reprobed them with a 600 bp-long PCR ampliﬁed fragment from the
porcine hepatic nuclear factor-1 (HNF1) gene using primers TCF1/F
50-CCCAGCAGATCCTGTTC-30 and TCF1/R 50-CTCCGTGACA-
AGGTTGGAG-30.Fig. 2. EIAV transduced pig embryos and piglets. (A) Transduction of
porcine preimplanation embryos with EIAV lentiviral vector. GFP
expression in early morula derived from zygotes treated by perivitelline
injection of pONY8.7NCG. (B) Ten day old founder pigs #112, #113,
#114 and non-transgenic piglet #20.2.4. Fluorescence imaging
GFP auto-ﬂuorescence was detected using blue light illumination
(GFP excitation frequency 455–495 nm) with a barrier ﬁlter cut oﬀ
below 500 nm. For animal and wet tissue, this was with a GFSP-5
headset (Biological Laboratory Instruments, Budapest). Photomicro-
graphs of embryos were taken using a Zeiss Axiovert 25 Microscope
equipped with an Axiocam colour Digital camera and using Axiovision
software. The images were taken at either 200 or 400 magniﬁcations
and UV images were taken using a GFP ﬁlter. Photomicrographs of
organs were taken on a Leica MZ 111 Zoom dissecting microscope
ﬁtted with UV and a GFP ﬁlter and a Leica digital camera.3. Results
3.1. Generation of transgenic pigs
Approximately 70 pl of a high-titre (1.6 109 TU/ml)
preparation of an EIAV vector containing the CMV-GFP
expression cassette (Fig. 1) was injected into the perivitelline
space of fertilised porcine zygotes. Of 147 zygotes collected
from ﬁve donor animals, all were injected and 120 zygotes
subsequently transferred into ﬁve recipient gilts. Visualisation
of non-transferred embryos clearly showed GFP-positive 4/5-
cell stage embryos (Fig. 2A). Four pregnancies were carried to
term and 40 piglets born. Of the 40 piglets born, 37 (92%) were
transgenic by Southern blot and/or polymerase chain reaction
assay. Of these 37 animals, 34 piglets expressed GFP as visu-
alised by direct ﬂuorescence in comparison to non-transgenic
piglets (Fig. 2B). A further animal displayed mosaic GFP ex-
pression at postmortem; a total of 35 out of 37 transgenic
founder piglets expressed GFP (95%).
3.2. EIAV-delivered transgene expression
Lentiviral vectors integrate as a single-copy, however, ani-
mals can carry more than one lentivector. We have determined
Fig. 3. Founder pigs carry diﬀerent transgene copy-numbers. Repre-
sentative Southern blot of ScaI digested ear biopsy DNA (individual
piglets identiﬁed by number); M, GFP-transgenic mouse DNA. Blot
hybridised with probe against GFP, then stripped and re-probed with
porcine HNF1 to conﬁrm DNA digestion and estimate loading. Piglet
# 20 was non-transgenic (see Fig. 2).
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animals were still born and not analysed for transgene inte-
gration; all ﬁve were visibly expressing GFP) by Southern blot
analysis of ear biopsy DNA (Fig. 3). In these founder animals,
the number of lentiviral vectors present ranged from 1 to 5
copies, which is lower than the 1–20 copies (mean¼ 4.6) re-
ported for HIV-1 based vectors of similar titre [3].
Further analysis was carried out on founder animals sacri-
ﬁced at two months of age. GFP expression was observed in all
tissues tested (Fig. 4). Expression was observed in tissues de-
rived from each of the three embryonic lineages, e.g., skin fromFig. 4. Lentiviral transgene displays widespread expression. Whole
tissue images of representative 4 month old pig (pig # 30; male; three
transgene copies). Bright ﬁeld (A) and ﬂuorescent (B–H) images of
kidney (A,B), liver (C), lung (D), heart (E), pancreas (F), gut (G) and
testis (H).ectoderm (Fig. 2B), pancreas from endoderm and kidney from
mesoderm (Fig. 4).4. Discussion
Lentiviral vectors enable the eﬃcient delivery of transgenes
into the germline of mammals. To-date, all reports on lentiviral
transgenic mammals have used an HIV-1 based vector [1–4,
11–13]. We now show that a vector based on another lentivirus,
the EIAV, can also be used to eﬃciently generate transgenic
mammals.
In our study, 37 transgenic piglets were produced from 120
injected and transferred porcine zygotes. Thus, 31% of injected
eggs resulted in a transgenic founder piglet, which is dramat-
ically greater than the 1% usually attributed to other methods
of generating transgenic livestock [6]. This compares favour-
ably with HIV-1 based vector studies in pigs, where an eﬃ-
ciency of 13% (32 from 244 zygotes) was achieved [3]. Both
vectors are associated with an extremely high expression fre-
quency in the founder animals; 93% for HIV-1 based vector
[1,3] and 95% for the EIAV-based vector.
Lentiviral vector transgene delivery demonstrates increased
eﬃciency over pronuclear injection at several stages. First, this
study was characterised by a high pregnancy rate (four of ﬁve
recipient animals carried their pregnancy to term), presumably
facilitated by the reduced physical intervention that perivitel-
line space injection oﬀers over standard pronuclear injection.
Second, nearly all founder animals are transgenic and third,
most of these founder animals express the transgene. These last
two properties are in stark contrast to that obtained by pro-
nuclear injection and nuclear transfer [6]. In this study, we
transferred 24 embryos per female pig recipient, which is more
than a gilt that could normally take to term. Given the very
high transgenesis rate, it is likely that many of the embryos
that did not develop to term were also transgenic. It is possible,
therefore, that if fewer embryos were transferred per recipient
female then an even greater overall eﬃciency may be achieved.
Furthermore, VSV-G pseudotyped lentivectors oﬀer the pos-
sibility to perform gene transfer studies in a wide range of
species, including those currently not suited to standard
transgenic methods, as well as less typical inbred strains of
mice. In addition, there is the exciting option of sequential
addition of transgenes to established transgenic lines.
To balance these positive aspects, there are some limitations
to lentivectors. First, lentivectors have an upper limit on the
cloning capacity of about 8 kb. This will limit the type of gene
construct that can be studied. Currently, there is no control
over the number or location of integration events. In our
study, we detected between one and ﬁve integrated copies,
while in the previous HIV-based study in pigs up to 20 copies
were reported [3]. This presents a breeding issue, as each in-
tegration event will segregate independently in subsequent
generations. We are maintaining some animals to allow
transmission and segregation issues to be assessed and will
report these data at a later date.
In conclusion, we have demonstrated that EIAV-based len-
tiviral vectors, in a similar manner to HIV-1 based vectors
[1–4,11–13], represent an extremely eﬃcient transgene delivering
method. This suggests that lentiviral transgene deliverymay be a
general tool with which to eﬃciently generate transgenic mam-
mals oﬀering exciting opportunities in livestock [6].
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